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What’s new? 
o Lower extremity amputation increases morbidity and risk of early death. 
o Diabetes is one of the most important risk factors for lower extremity amputation. 
o Over the last 20 years the incidence rates of amputation have declined significantly 
in people with and without diabetes. 
o The results of this study support the idea that amputation is generally avoided at a 
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Aim To investigate the trends in non-traumatic lower limb amputation in people with and without 
diabetes.  
Methods From the Danish National Patient Register, all people with either type 1 or type 2 diabetes 
(n = 462 743) as well as a group of people without diabetes from the general population (n = 1 388 
886) were identified and separated into three groups based on diabetes type. Among these, 17 265 
amputations were identified between 1997 and 2017 and stratified into trans-femoral amputations, 
trans-tibial amputations and amputations below the ankle using surgical codes. Annual changes 
were described using least-squares linear regression. 
Results The yearly mean decrease in incidence rate of amputation per 1000 person-years was  --
0.032 [95% CI: -0.062, -0.001],  -0.022 [-0.032, -0.012] and  -0.006 [-0.009, -0.003] for trans-
femoral amputation,  -0.072 [-0.093, -0.052], -0.090 [-0.102, -0.078] and  -0.015 [-0.016, -0.013] 
for trans-tibial amputation, and -0.055 [-0.080, -0.020],  -0.075 [-0.090, -0.060] and -0.011 [-0.014, 
-0.007] for amputation below the ankle in people with type 1 diabetes, people with type 2 diabetes 
and people without diabetes, respectively.  
Conclusions: Over recent decades, the incidence of amputation has decreased significantly in 
people with diabetes and in the general population without diabetes.   
<Typesetter: Format the reference citations throughout the text in the DME journal style, thanks.> 
<H1>Introduction 
Foot disease in people with diabetes may affect as many as 6% of people with diabetes and includes 
infection, ulceration, or destruction of tissues of the foot [1]. The various forms of foot disease may 
impair quality of life and also affect social participation and livelihoods [2]. Between 0.03 and 1.5% 
of the general inpatient population with diabetes may require an amputation during their hospital 
stay [3], and the 5-year mortality after foot amputation might be as high as 74%, which rivals many 
forms of cancer [4]. A recent Danish study identified atherosclerosis (70%), hypertension (53%) 










and diabetes (49%) as the most common precursors of amputation in the general population [5], but 
only a fraction of people with those risk factors will end up requiring an amputation. Over recent 
decades, there has been an increasing interest in amputation prevention as well as revascularization, 
and several studies have been conducted regarding the impact of revascularization on the incidence 
of amputation and mortality [6–8]. A recent systemic review on the incidence of non-traumatic 
lower limb amputation in people with and without diabetes demonstrated a considerable variation in 
incidence and trends of amputation in people with diabetes, concluding that further studies with 
comparable designs were needed [9]. Despite the moderate number of studies investigating trends in 
lower extremity amputation in the early 2000s and 2010s, only a few recent studies exist [10,11]. 
Therefore, this study sought to investigate the trends in lower limb amputation in people with and 
without diabetes in a large Danish national cohort over a 20-year period. Revascularization and 
mortality were also studied as secondary endpoints.   
<H1>Design and Methods 
<H2>Data source 
This retrospective cohort study used data from the Danish National Patient Register, which is one of 
the world’s oldest nationwide hospital registries. The Danish National Patient Register is a 
population-based administrative registry collecting data from all Danish hospitals since 1977, with 
complete nationwide coverage since 1978 [12]. All data from the Danish National Patient Register 
can be linked at patient level with data from clinical registries, randomized controlled trials, 
population surveys, epidemiological field studies and other Danish administrative registries [12] 
including The Danish National Prescription Registry, which has been collecting data on drug 
prescriptions since 1996 [13]. 
<H2>Study population 
Through the national registries we identified 462,743 people with diabetes using the International 
Classification of Diseases and Related Health Problems (ICD-10) codes for diabetes (ICD10: 










E10.X) and the Anatomical Therapeutic Chemical (ATC) classification system for anti-diabetic 
medicine including insulin between 1997 and 2017 (ATC: A10A.X, A10B.X). Participants were 
included in the year of their diagnosis or match. Using this method, the diabetes prevalence in 2017 
was 5.1%. People with diabetes were defined as having type 1 diabetes if they had an ICD-10 code 
for type 1 diabetes (E10.X), had received insulin (A10A.X), but no other antidiabetic drug 
(A10B.X). If people with diabetes did not meet the criteria for type 1 diabetes then they were 
defined as having type 2 diabetes. It was attempted that all people with diabetes were matched 1:3 
by year of age and sex with people without diabetes from the general population, although this was 
not entirely possible due to a lack of people without diabetes with matching age and sex. 
Participants could not switch between groups and could not appear more than once. Participants 
could not have had a previous amputation before entering the study. This was ensured, as surgical 
codes were available from 1977 onwards. Participants aged <18 years or without a Danish Social 
Security Number were excluded. Revascularizations, defined as both surgical and percutaneous 
techniques, were identified within the cohorts receiving an amputation using surgical codes (Table 
S1). Mortality data were reported from the Danish Cause of Death Register. Characteristics for each 
group at the time of amputation are displayed in Table 1. 
<INSERT TABLE 1> 
 
<H2>Outcomes 
Our primary endpoint was incidence rate of trans-femoral amputation, trans-tibial amputation and 
amputation below the ankle for people with type 1 diabetes, people with type 2 diabetes and people 
without diabetes. Our secondary endpoints were revascularization and all-cause mortality. Our 
cohort was followed from year of inclusion until year of death, end of data collection, end of study 
period (31 December 2017), or the year of first amputation, whichever came first.  
<H2>Statistical analysis 










For our primary endpoint we calculated incidence rates as the number of amputations per 1000 
person-years. This was accomplished by dividing the number of events in each group by the total 
number of persons at risk in that group for a given year then multiplying by 1000. Annual changes 
were estimated using least-squares linear regression.  
 For our secondary endpoints, we displayed the percentage of amputations with preceding 
revascularization, which were found by using the surgical codes mentioned above within the cohort 
of people undergoing amputation. The time from first revascularization to first amputation was 
calculated as the time that had elapsed between the dates of each occurring. People with type 1 
diabetes were not included in the revascularization analysis, as the number of events in this group 
was too small to display any useful trend. Mortality was analysed by Kaplan-Meier survival 
analysis. This analysis was only performed in the people receiving an amputation. Differences were 
described using a log-rank test.   
   The data that support the findings of this study are available from Statistics Denmark, but 
restrictions apply to the availability of these data, which were used under licence for the current 
study and therefore are not publicly available. Data are, however, available from the authors upon 
reasonable request and with permission from Statistics Denmark. 
 All analyses were performed using STATA Release 15 (StataCorp, College Station, TX, USA). 




We identified a total of 1,851,629 participants in our study. Among these, we initially identified 
28,034 amputations using surgical codes (Table S1) performed at one of the 23 centres performing 
amputation in Denmark; 597 amputations were removed as they were duplicates caused by double 
registration; 332 were removed as they were caused by trauma; and 278 had more than one surgical 










procedure registered on the same date. In this case, we selected only the most proximal amputation 
and excluded the rest. Finally, we selected only the first amputation per person, excluding a further 
9562 amputations, leaving us with 17,265 amputations. These were distributed with 6,950 
amputations among people without diabetes and 10,315 among people with diabetes. The 
distribution between the different amputation sites is displayed in Figure 1. As knee disarticulations 
were rare, they were included in the group containing trans-tibial amputation. 
<INSERT FIGURE 1>  
Over the last 2 decades, the total number of amputations has increased significantly in people with 
diabetes and in the general population without diabetes (P < 0.001; Table S2). However, the trend 
in incidence rate per 1000 person-years is different, as a significant yearly decrease is seen in all 
groups at all sites. For people with type 1 diabetes, the mean decrease is -0.032 [-0.062, -0.001] for 
trans-femoral amputation, -0.072 [-0.093, -0.052] for trans-tibial amputation and -0.055 [-0.080, -
0.020] for amputation below the ankle. For people with type 2 diabetes, the decrease is -0.022 [-
0.032, -0.021] for trans-femoral amputation, -0.090 [-0.102, -0.078] for trans-tibial amputation and -
0.075 [-0.090, -0.060] for amputation below the ankle. For people without diabetes, the decrease is -
0.006 [-0.009, -0.003] for trans-femoral amputation, -0.015 [-0.016, -0.013] for trans-tibial 
amputation and -0.011 [-0.014, -0.007] for amputation below the ankle. The results are displayed in 
Figure 2. Group characteristics are available in Table 1.
<INSERT FIGURE 2>  
<H2>Revascularization 
Over the last 20 years, the total number of revascularizations in people later undergoing amputation 
has increased significantly at all sites for people with type 2 diabetes (all P < 0.001) and for people 
without diabetes (all P < 0.001; Table S2).  










Describing trends in revascularization as the percentage of amputations with preceding 
revascularization, no significant changes were found in any group at any site. Results are displayed 
in Figure 3. 
<INSERT FIGURE 3>  
  Investigating time from first revascularization until first amputation, a significant increase was 
seen before trans-femoral amputation, trans-tibial amputation and amputation below the ankle in 
people with type 2 diabetes (all P < 0.001) and in people without diabetes (P < 0.001, P = 0.002 and 
P < 0.001, respectively). Results are displayed in Figure 4. 
<INSERT FIGURE 4>  
<H2>Mortality 
Mortality data showed excess mortality in people with type 1 diabetes and in people with type 2 
diabetes compared with people without diabetes in the time after amputation below the ankle (all P 
< 0.001). However, only people with type 2 diabetes displayed statistically significant excess 
mortality compared with people without diabetes after trans-tibial amputation (P = 0.002), although 
mortality appeared comparable within the first months after surgery. None of the cohorts with 
diabetes displayed statistically significant excess mortality after trans-femoral amputation compared 
with people without diabetes. The results are displayed as Kaplan-Meier survival analysis in Figure 
5. 
<INSERT FIGURE 5>  
<H1>Discussion 
Data from this study reveal that the incidence rate of trans-femoral amputation, trans-tibial 
amputation and amputation below the ankle has decreased significantly in people with type 1 
diabetes, in people with type 2 diabetes, and in the general population without diabetes in Denmark 
between 1997 and 2017. While all groups have experienced declines, people with type 1 diabetes 
and people with type 2 diabetes have experienced larger declines than people without diabetes. This 










trend could be because people without diabetes do not receive frequent medical checks, as is the 
case for people with diabetes, and are thereby being detected at a later stage, while prophylactic 
treatment for risk factors like high cholesterol or high blood pressure may also be neglected. Also, 
the difference could be due to the fact that people with diabetes generally are amputated at a much 
higher rate, which makes improved prevention more impactful. Finally, part of the difference could 
be attributable to the implementation of multidisciplinary diabetic foot clinics, where a 
multidisciplinary team of specialists assess the diabetic foot. This is also in contrast to amputation 
in the group of people without diabetes, where people do not necessarily receive optimal medical 
treatment, and the decision to amputate might be based on the assessment of a non-specialized 
surgeon. It should also be noted, however, that a decline is seen in all groups at all sites, indicating a 
general improvement which is not specific to people with diabetes. This could be caused by better 
risk factor control or an increased focus on preventive strategies such as revascularizations. Also, it 
could be due to changes in the acute management of lower limb ulcers as well as a higher threshold 
for amputation. 
  Data from this study also show that the percentage of amputations with preceding 
revascularization has not changed significantly between 1997 and 2017. The lack in improvement is 
generally driven by the fact that the number of amputations has increased at the same rate as the 
number of revascularizations, thereby keeping the percentage at the same level. However, the data 
did reveal a significant increase in the time between the first revascularization and the need for 
amputation, indicating an improvement in the treatment, which is probably caused by improvements 
in skills and technical equipment, or that revascularizations are happening earlier due to better 
monitoring and care by multidisciplinary units, including earlier detection of peripheral arterial 
disease. It should be noted, however, that this study only analysed data from the first 
revascularization to first amputation, which means that we cannot know if the result is indeed 










caused by better techniques or rather by the implementation of a higher number of re-
revascularizations before people are admitted to surgery.  
Mortality data from this study display excess mortality for people with type 1 diabetes and for 
people with type 2 diabetes following amputation below the ankle, while only people with type 2 
diabetes displayed excess mortality compared with people without diabetes after trans-tibial 
amputation. No significant difference in post-amputation mortality was found in people with type 1 
diabetes or in people with type 2 diabetes compared with people without diabetes following trans-
femoral amputation. As the group of people without diabetes was in general older at the time of first 
amputation than the two groups with diabetes, this excess mortality is probably caused by diabetes 
and its co-morbidities, rather than by an age difference. Mortality rates from this study reinforce 
previous findings of high mortality following amputation. In a recent systemic review on early post-
operative mortality after major lower limb amputation, the authors found a 30-day mortality ranging 
from 7 to 22% including all patients. The authors concluded that the mortality rates were higher 
after trans-femoral amputation than trans-tibial amputation, with no significant difference between 
people with and without diabetes [14]. In two other recent reviews regarding the impact of foot 
ulcers on amputation and mortality [15,16], the authors found that the 5-year mortality following 
above-knee amputation ranged from 40 to 90%, while the 5-year mortality rate following below-
knee amputation ranged from 40 to 82%. Inconsistencies regarding the impact of diabetes on 5-year 
mortality were also reported, as results from the different studies included varied greatly. These 
results are in line with the results from our study, where people with diabetes in general displayed 
higher mortality rates than people without diabetes when the amputation being performed was more 
distal. Whether excess mortality has increased or decreased over recent decades is not examined 
any further in this study, but this factor could be explored in future research focusing on post-
amputation mortality.  










  Our results regarding the incidence of amputation and development in revascularizations are only 
partly consistent with data reported in comparable European countries. Using data derived from the 
German Federal Statistical Office between 2005 and 2014, Kröger et al. [17] and Moysidis et al. 
[18] described an increase in the absolute number of admissions due to peripheral arterial disease 
and/or neuropathic vascular disease, with a simultaneous increase in minor amputation and a 
corresponding decrease in major amputation. In the UK, Vamos et al. [19] reported a significant 
increase in the absolute number of lower extremity amputation between 2004 and 2008, while the 
rates of both minor and major amputation showed a non-significant trend towards a decline. In 
Scotland, Kennon et al. [20] found a significant reduction in the incidence of lower extremity 
amputation in people with diabetes between 2004 and 2008, while data from the northern 
Netherlands further supports this, reporting a decrease for people with diabetes between 1991 and 
2013 [21]. Recent studies have also been conducted in Spain [22], Romania [23] and Ireland[24], 
but in general the results lack consistency, and there appears to be divergence between results even 
within the same country. Several large studies are available from the USA [25–28] and Australia 
[29]. In the USA, a general trend seems to favour a decrease in major amputation, with a significant 
increase in endovascular intervention. The reasons behind these divergent results are probably 
multifactorial, but varying data quality and lack of registration may also play important roles, while 
the choice of whether to include all amputations or just the first amputation could also be a 
contributing factor. Another reason could be possible selection bias in studies performed in one or 
more centres. Large hospitals in larger cities may have better or poorer registration than smaller 
rural hospitals, and there might be a large divergence among those people admitted at different 
sites. Furthermore, highly specialized endovascular centres might have different outcomes than 
hospitals without specialized units. In Denmark, only 23 centres perform amputation. They are all 
public centres, and the guidelines they follow are more or less uniform throughout the country. 










Furthermore, multidisciplinary foot clinics are being implemented in increasing fashion, 
contributing to declining amputation rates, even in amputation below the ankle.  
  In the current study, we used a large nationwide database including all people diagnosed with 
diabetes in Denmark, thereby excluding the possibility of selection bias. In addition, we identified 
diabetes using ICD-10 codes and prescription data, which yields a much higher certainty of correct 
registration than ICD-10 codes alone. Furthermore, we used surgical codes when defining events, 
which have proven to be very reliable [12]. This study has several inherent limitations, however, 
mostly due to our study design. First, we chose to identify type 1 diabetes with great certainty, 
which probably caused us to underestimate prevalence and limited our cohort size to an extent 
where some of the trends we wished to study did not yield either statistical significance or a useful 
trend due to limited observations. Second, we defined type 2 diabetes as all people with diabetes 
except for those people included in the type 1 diabetes group. This gave us greater statistical power 
when analysing the data and allowed us to study the entire population of people with diabetes in 
Denmark, including people only seen in the primary care setting, and it did not change the trends 
for the groups. However, it did make the group more heterogeneous, as it probably included a few 
people with type 1 diabetes. Third, we chose to include only the first amputation and first 
revascularization for each person, which limits our data to describing trends in first amputation and 
revascularization, and not in the overall rate. 
  In conclusion, the incidence rate of amputation in people with diabetes and in the general 
population has decreased significantly over the last 2 decades, with an increasing focus on limb-
salvaging surgery. The percentage of revascularization preceding amputation remains constant, with 
increasing times between first revascularization and the need for amputation. However, further 
studies are needed to examine the reason behind the ongoing excess mortality seen in people with 
diabetes following amputation.    











Preliminary results from this study were presented at the International Symposium on the Diabetic 
Foot, 2019, and at the 55th annual meeting of the European Association for the Study of Diabetes, 
2019. 
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Figure 1 Flowchart of amputations studied. The numbers are amputations in each group. At the bottom the 
amputations are divided into groups based on amputation site. 
 
Figure 2 Trends in incidence rates (IR) per 1000 person-years for (a) trans-femoral amputation, (b) trans-tibial 
amputation and (c) amputation below the ankle, in people with type 1 diabetes, in people with type 2 diabetes 
and in people without diabetes, respectively. As trans-femoral amputation was rare in people with type 1 
diabetes, no amputations were observed in some years.  
 
Figure 3 Trends in the percentage of amputations with preceding revascularization before (a) trans-femoral 
amputation, (b) trans-tibial amputation and (c) before amputation below the ankle.  
 Figure 4 Trends in time between first revascularization and first amputation for (a) trans-femoral amputation 
(b) trans-tibial amputation and (c) amputation below the ankle. Time between the two events are displayed in 
years.  
 
Figure 5 Kaplan-Meier post-amputation survival analysis after (a) trans-femoral amputation, (b) trans-tibial 
amputation and (c) amputation below the ankle. The vertical lines indicate survival 1 and 5 years after 
amputation.  
  












Table 1 Group characteristics at the time of trans-femoral amputation, trans-tibial amputation or amputation 
below the ankle for people with type 1 diabetes, people with type 2 diabetes and people without diabetes 
 People with type 
1 diabetes 
People with 




Number of amputations 







Mean age (men/women) 67/77 years 73/78 years 75/81 years 
Sex (men/women) 56/44% 55/45% 54/46% 
Preceding revascularization 32% 20% 23% 











Number of amputations 







Mean age (men/women) 63/59 years 71/76 years 73/78 years 
Sex (men/women) 71/19% 62/38% 60/40% 
Preceding revascularization 12% 18% 24% 










Amputation below the ankle 
Number of amputations 







Mean age (men/women) 59/68 years 68/73 years 72/72 years 
Sex (men/women) 78/22% 74/26% 61/39% 
Preceding revascularization 18% 18% 19% 




















































































































































Trends in trans-femoral amputations
People with type 2 diabetes.
Yearly trend: -0.022 (-0.032, -0.012)
People with type 1 diabetes.
Yearly trend: -0.032 (-0.062, -0.001)
People without diabetes.


















































































































Trends in trans-tibial amputations 
People with type 2 diabetes.
Yearly trend: -0.090 (-0.102, -0.078)
People with type 1 diabetes.
Yearly trend: -0.072 (-0.093, -0.052)
People without diabetes.




















































































































Trends in amputations below the ankle
People with type 2 diabetes.
Yearly trend: -0.075 (-0.090, -0.060)
People with type 1 diabetes.
Yearly trend: -0.055 (-0.080, -0.020)
People without diabetes.



















































































































































Trends in revascularization before trans-femoral amputation
People with type 2 diabetes.
Yearly trend: 0.137 (-0.229, 0.504)
People without diabetes.










































































































































Trends in revascularization before trans-tibial amputation
People with type 2 diabetes.
Yearly trend: 0.240 (-0.045, 0.525)
People without diabetes.










































































































































Trends in revascularization before amputation below the ankle
People with type 2 diabetes.
Yearly trend: -0.234 (-0.482, 0.015)
People without diabetes.




















































































































Mean time from revascularization to trans-femoral amputation 
People with type 2 diabetes.
Yearly trend: 0.177 (0.126, 0.229)
People without diabetes.










































































































Mean time from revascularization to trans-tibial amputation 
People with type 2 diabetes.
Yearly trend: 0.167 (0.124, 0.211)
People without diabetes.











































































































Mean time from revascularization to amputation below the ankle
People with type 2 diabetes.
Yearly trend: 0.061 (0.033, 0.089)
People without diabetes.
Yearly trend: 0.086 (0.046, 0.125)
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